T-Cell Lymphoma Clinical Trials 2023

What are the top hospitals conducting t-cell lymphoma research?

When it comes to cutting-edge clinical trials in the realm of T-cell lymphoma, several esteemed hospitals are leading the charge. In Boston, the renowned Dana-Farber Cancer Institute has emerged as a frontrunner with two ongoing trials focused on this specific type of lymphoma. With a total of 16 completed trials dedicated to T-cell lymphoma since their pioneering trial in 2005, this institution has been at the forefront of research and innovation.

On the other side of the country, Oregon Health & Science University in Portland is making notable strides in T-cell lymphoma research as well. They currently have two active clinical trials centered around this condition and have documented a total of five trials since their first investigation commenced just six years ago in 2015.

Further south lies another prominent player: The University of Alabama at Birmingham is spearheading groundbreaking efforts with its two ongoing T-cell lymphoma trials. Since initiating their inaugural study in 2008, they have contributed significantly to our understanding and treatment options for this complex disease through eleven conducted investigations.

Meanwhile, back on the East Coast, Memorial Sloan-Kettering Cancer Center located in New Yorkf Alabama at Birmingham is spearheading groundbreaking efforts with its two ongoing T-cell lymphoma trials. Since initiating their inaugural study in 2008, they have contributed significantly to our understanding and treatment options for this complex disease through eleven conducted investigations.

Meanwhile, back on the East Coast, Memorial Sloan-Kettering Cancer Center located in New York City also stands out for its commitment to advancing knowledge about T-cell lymphoma. Alongside two active clinical trials tackling this disease head-on, their illustrious history includes fifteen previously executed studies dating all the way back to 2001 when they recorded their initial trial dedicated to exploring therapeutic approaches for patients with T-cell lymphomas.

It's worth noting that Dana Farber Cancer Institute once again makes an appearance on this list due to its unwavering dedication to combating T-cell lymphoma. Similar to other top institutions mentioned earlier, they possess an impressive record comprising seventeen past studies while concurrently conducting two active clinical trials since embarking upon their very first investigation concerning t cell-lymphomas15 years ago,in2006

These exceptional hospitals highlight not only progress but also hope for individuals affected by T-cell lymphoma. Their commitment to clinical research and innovative approaches underscores the collective efforts aimed at unraveling the mysteries surrounding this complex condition, ultimately leading to improved treatment options and better outcomes for patients worldwide.

Which are the best cities for t-cell lymphoma clinical trials?

When it comes to clinical trials for t-cell lymphoma, several cities have emerged as top contenders in advancing research and treatment. New York leads the way with 8 active trials investigating promising options such as ONO-4685, IPH4102, and Tagraxofusp. Boston follows closely behind with 6 ongoing studies focused on CPI-0209, Tagraxofusp, CAR-37 T cells, among others. Chicago and Philadelphia both boast 5 active trials exploring treatments like CPI-0209, IPH4102, Nivolumab and EPOCH (combination therapy), while Charlotte showcases 4 studies investigating Duvelisib, Tagraxofusp, ONO-4685. These cities offer individuals diagnosed with t-cell lymphoma access to cutting-edge clinical trials that seek to improve outcomes and provide hope for a brighter future.

Which are the top treatments for t-cell lymphoma being explored in clinical trials?

Exciting progress is being made in clinical trials exploring treatments for T-cell lymphoma. One standout contender is tagraxofusp, which has shown promise in one active trial dedicated to treating this form of lymphoma since its listing in 2022. Another noteworthy player is STP938, also involved in a single ongoing trial and first listed just recently in 2022. Additionally, ONO-4685 and CAR-37 T cells are gaining attention with their own individual trials, each boasting one all-time study and demonstrating potential as treatment options for T-cell lymphoma patients. As research progresses on these innovative therapies, hope grows stronger for improved outcomes against this challenging disease.

What are the most recent clinical trials for t-cell lymphoma?

Recent clinical trials have shown promising results for the treatment of t-cell lymphoma. Notably, a Phase 2 trial investigated the combination of mogamulizumab and DA-EPOCH, offering potential benefits for patients. Additionally, a Phase 1 trial explored the use of tagraxofusp as a therapeutic option. Another Phase 2 study focused on mogamulizumab as an independent treatment for t-cell lymphoma. Furthermore, investigations into STP938 in both Phase 1 and Phase 2 trials revealed encouraging findings. Although slightly earlier in development, ONO-4685 showed promise in its Phase 1 trial conducted late last year. These recent clinical trials provide hope for improved outcomes and novel approaches to tackling t-cell lymphoma.

What t-cell lymphoma clinical trials were recently completed?

Recently concluded clinical trials have made significant strides in the field of T-cell lymphoma research. Completed in June 2019, a trial sponsored by the National Cancer Institute (NCI) focused on rhIL-15, an innovative therapy with promising potential. Additionally, CStone Pharmaceuticals successfully completed their CS1001 trial in June 2018, while Weill Medical College of Cornell University's CC-486 Administration study also reached fruition during the same month and year. Although slightly older but worth noting for historical context, Stanford University finished a trial investigating anti-thymocyte globulin back in May 2009. These advancements reflect ongoing efforts to improve treatment options for individuals affected by T-cell lymphoma and bring hope to patients battling this challenging disease.